PDCD1 and hepatocellular carcinoma: In a phase I/II trial, cabozantinib (TKI) 40 mg daily with nivolumab (anti-PD-1) 240 mg on the first day after 2 weeks (double immunotherapy) or nivolumab 3 mg/kg after 2 weeks plus cabozantinib 40 mg daily, with ipilimumab (anti-CTLA-4) 1 mg/kg after 1.5 months (triple immunotherapy) were given to HCC patients who had not responded to sorafenib.